Menu
Cellaïon is a biotechnology company established in 2021 that develops cellular therapy using the anti-inflammatory and regenerative signaling properties of liver stem cells.
GENFIT stands as a global leader in the biotechnological sector, specializing in the discovery and development of therapeutics for liver diseases, with a particular focus on acute-on-chronic liver failure (ACLF).
Grifols S.A. is a global healthcare company founded in 1909, leader in essential plasma-derived and transfusion medicines.
Since 2022, Versantis is part of GENFIT. Versantis GmbH is a clinical-stage pharmaceutical company developing a new generation of orphan medicines to treat rare pediatric and acute liver diseases.
European Foundation for the Study of
Chronic Liver Failure
Travessera de Gràcia 11, 7th floor
08021 Barcelona, Spain
© European Foundation for the Study of Chronic Liver Failure 2024
